[1] Aarskog D. A familial syndrome of short stature associated with facial dysplasia and genital anomalies[J]. J Pediatr,1970,77(5):856-861.
[2] Orrico A, Galli L, Clayton-Smith J, et al. Clinical utility gene card for: Aarskog-Scott syndrome(faciogenital dysplasia) - update 2015[J]. Eur J Hum Genet,2015,23(4).doi:10.1038/ejhg.2014.178.
[3] Zanetti DV, Sousa SL, Sousa SC, et al. The prevalence of clinical features in patients with Aarskog-Scott syndrome and assessment of genotype-phenotype correlation: A systematic review[J]. Genet Res(Camb),2021,2021:6652957.
[4] Ge Y, Li N, Wang Z, et al. Novel variant in the FGD1 gene causing Aarskog-Scott syndrome[J]. Exp Ther Med,2017,13(6):2623-2628.
[5] Jia H, Ma T, Liu Z, et al. A novel frameshift mutation in the FGD1 gene causing Aarskog-Scott syndrome patient with hypogonadism: A case report[J]. Transl Pediatr,2021,10(5):1377-1385.
[6] Zhu Y, Chen Q, Lin H, et al. FGD1 Variant associated with Aarskog-Scott syndrome[J]. Front Pediatr,2022,10:888923.
[7] 刘子勤,陈晓波,邱明芳.Aarskog-Scott综合征一例报道[J].中华内分泌代谢杂志,2020,36(3):253-256.
Liu ZQ, Chen XB,Qiu MF. A case report of Aarskog Scott syndrome[J]. Chin J Endocrinol Metab, 2020,36(3):253-256.(in Chinese)
[8] 黄雪娇, 黎芳, 麻宏伟. Aarskog-Scott综合征1例报告及文献复习[J]. 发育医学电子杂志, 2023, 11(3): 205-207.
Huang XJ, Li F, Ma HW. A case report and literature review of Aarskog Scott syndrome[J]. Journal of Developmental Medicine(Electronic Version),2023, 11(3): 205-207.(in Chinese)
[9] 王冉, 裴晶晶, 蒋新液,等. 一例Aarskog-Scott综合征患儿的FGD1基因变异分析[J].中华医学遗传杂志,2021, 38(8):757-760.
Wang R, Pei JJ, Jiang XY, et al. Analysis of FGD1 gene variation in a child with Aarskog Scott syndrome[J]. Chin J Med Genet, 2021, 38(8):757-760.(in Chinese)
[10] Volter C, Martinez R, Hagen R, et al. Aarskog-Scott syndrome: A novel mutation in the FGD1 gene associated with severe craniofacial dysplasia[J]. Eur J Pediatr,2014,173(10):1373-1376.
[11] Wu W, Jing DD,Meng ZB, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity[J]. Theranostics,2020,10(6):2859-2871.
[12] Murphy NP,Binti Ahmad Mokhtar AM, Mott HR, et al. Molecular subversion of Cdc42 signalling in cancer[J]. Biochem Soc Trans,2021,49(3):1425-1442.
[13] Zeng YL, Guo ZY, Hu ZG, et al. FGD1 exhibits oncogenic properties in hepatocellular carcinoma through regulating cell morphology, autophagy and mitochondrial function[J]. Biomed Pharmacother, 2020,125:110029.
[14] Niu ZH, Li Y, Xu YJ, et al. Silencing FYVE, RhoGEF, and PH domain containing 1(FGD1) suppresses melanoma progression by inhibiting PI3K/AKT signaling pathway[J]. Bioengineered,2021,12(2):12193-12205.
[15] Darendeliler F, Larsson P, Neyzi O,et al. Growth hormone treatment in Aarskog syndrome: Analysis of the KIGS(Pharmacia International Growth Database) data[J]. J Pediatr Endocrinol Metab,2003,16(8):1137-1142.
[16] Al-Semari A, Wakil SM, Al-Muhaizea MA, et al. Novel FGD1 mutation underlying Aarskog-Scott syndrome with myopathy and distal arthropathy[J].Clin Dysmorphol,2013,22(1):13-17.
[17] Bayat A, Krett B, Duno M, et al. Novel truncating variants in FGD1 detected in two Danish families with Aarskog-Scott syndrome and myopathic features[J]. Am J Med Genet A,2022,188(7):2251-2257.
[18] Park J, Moon YJ, Kim DS. Miyoshi muscular dystrophy type 1 with mutated DYSF gene misdiagnosed as Becker muscular dystrophy:A case report and literaturereview[J]. Genes(Basel),2023,14(1):200.
[19] Nashi S, Polavarapu K, Bardhan M, et al. Genotype-phenotype correlation and natural history study of dysferlinopathy:A single-centre experience from India[J]. Neurogenetics,2023,24(1):43-53.
[20] Bae GY, Kim MS, Kim JY, et al. The first Korean family with Aarskog-Scott syndrome harboring a novel mutation in FGD1 diagnosed via targeted gene panel sequencing[J]. Ann Clin Lab Sci, 2020,50(5):691-698.